Fierce Biotech: Dotmatics debuts antibody engineering R&D software platform
Dotmatics has launched an AI-driven Antibody Engineering software platform aimed at accelerating and optimizing antibody design and development in life sciences R&D, as detailed in a Fierce Biotech article by Connor Hale.
In a recent Fierce Biotech feature, author Connor Hale discusses Dotmatics' innovative Antibody Engineering software platform. This platform is designed to accelerate and optimize research and development for life sciences organizations. Leveraging advanced AI-driven tools, the platform enhances the precision and speed of antibody design and development. The article highlights how this innovation is poised to transform antibody research and drive breakthrough discoveries.
To learn more about how Luma can transform your R&D process, you can read the full article on Fierce Biotech.
Related
Meet Dotmatics at PEGS Boston 2026 — Booth #304
Dotmatics will exhibit at PEGS US 2026 in Boston from May 11-15 at booth #304, showcasing their Luma platform and antibody solutions during the summit focused on protein and antibody engineering, with a new emphasis on peptide therapeutics.
Discover Dotmatics: San Diego
On October 30, 2024, from 5:30pm to 8:00pm at Gravity Heights in San Diego, industry leaders including Dotmatics' Phil Mounteney and Andrew LeBeau, along with BioGlyph's CEO Fernando Garces, will host a networking event featuring discussions on innovation at the science-technology interface, a live demo of Dotmatics Luma, and updates on upcoming releases, all accompanied by dining and drinks.
Addressing Inefficient R&D Workflows
The blog discusses how legacy, fragmented R&D systems hinder innovation in complex, multi-domain scientific research by creating silos and inefficiencies, and presents Dotmatics’ unifying platform as a comprehensive solution that integrates diverse tools, data, and teams to enable smarter collaboration, governed data use, and AI-driven automation for faster, more rigorous innovation.
Dotmatics Launches BioGlyph Luma to Accelerate the Future of Protein Design & Engineering
Dotmatics has launched BioGlyph Luma, a next-generation protein design and engineering solution integrated into its Luma Scientific Intelligence Platform, which addresses the Design phase of the protein therapeutics research cycle by enabling real-time traceability, scalable registration, and seamless integration with existing scientific tools to accelerate multimodal biologic R&D workflows with precision and data-driven automation.
Leveraging Informatics and Modeling Tools to Develop a Comprehensive Design Make and Test Platform
LifeArc, a UK medical research charity focused on developing diagnostics and therapeutics for diseases like cancer and autoimmune disorders, utilizes the Dotmatics Platform to integrate and streamline their entire Design-Make-Test research cycle by uniting internal and external collaborators, automating data acquisition, and providing seamless access to predictive modeling, informatics, and AI/ML tools for small molecule and antibody discovery while protecting intellectual property.
The Antibody Engineering & Therapeutics Conference
Dotmatics is sponsoring the Antibody Engineering & Therapeutics US 2022 conference on December 5 at Marriott Marquis San Diego, featuring innovations in antibody discovery and related fields, with a highlighted talk by Senior Solutions Architect Melanie Nelson on streamlining antibody discovery using Dotmatics Biology Solution from 1:15pm to 1:45pm PST at Booth 509.